ALB and hepatocellular carcinoma: Concerning expression levels, MET is overexpressed in 86% (6/7) of HCC patients belonging to subgroup-3 (which best overlaps with CGI methylation changes in Alb-R26Met), in 32% (6/19) to HCC subgroup-2, and only in 13% (2/15) to HCC subgroup-1 (Fig. 1f; patients with MET overexpression are highlighted with a red dot; Supplementary Fig. 3C–F).